Before any other changes, the fatty coating on peripheral nerve fibers breaks apart, heralding their degeneration.
Researchers at SfN 2016 reported that oligomeric and exosomal forms in plasma predict AD as early as a decade prior to symptoms.
Cognitively normal people who harbor plaques in their brains are more likely to report feelings of isolation.
Methods that trawl body fluids for amyloidogenic proteins are getting more sensitive and specific, and scientists are expanding the repertoire of oligomers they can detect.
Diurnal variations disappear as less Aβ42 reaches cerebrospinal fluid. Findings may improve timing of daily amyloid treatments.
Convened by ARUK to learn from the antibody’s billion-dollar bust, industry and academic leaders declare insufficient CNS target engagement, say peripheral sink did not work, and brainstorm how to move forward.
In the field’s march toward automated testing, scientists for the first time used biomarker cutoffs determined in one cohort to predict amyloid accumulation in a second. It worked.
People with ALS—especially those who progress fast—express myriad inflammatory genes in their blood monocytes.
Analysis of brain tissue from Alzheimer’s patients offers a glimpse of proteomic changes in the disease.
At AAIC, researchers debuted a method that detects changes in plasma Aβ42 in people with brain amyloid. If confirmed, a widely available screening test for presymptomatic AD could follow.
Researchers at AAIC reinforced the idea that tau pathology drives cognitive decline, although amyloid plaques were implicated in semantic memory deficits.
Researchers at AAIC described different correlates of CSF and PET measures of Aβ and tau.
AAIC presentations identified early imaging changes in aging and AD, and reinforced the idea that CSF markers change little over the short term.
Researchers at AAIC presented several imaging measures that may help explain the phenomenon of preserved cognition in the face of AD pathology.
Tau in the plasma rises after traumatic brain injury, with cognitive decline, and progression to mild cognitive impairment.